DK3250208T3 - 7-benzyl-4-(4-(trifluormethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on og salte deraf samt anvendelse deraf i terapi - Google Patents

7-benzyl-4-(4-(trifluormethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on og salte deraf samt anvendelse deraf i terapi Download PDF

Info

Publication number
DK3250208T3
DK3250208T3 DK16744237.5T DK16744237T DK3250208T3 DK 3250208 T3 DK3250208 T3 DK 3250208T3 DK 16744237 T DK16744237 T DK 16744237T DK 3250208 T3 DK3250208 T3 DK 3250208T3
Authority
DK
Denmark
Prior art keywords
benzyl
hexahydroimidazo
pyrido
pyrimidin
trifluoromethyl
Prior art date
Application number
DK16744237.5T
Other languages
English (en)
Inventor
Richard S Pottorf
Bhaskara Rao Nallaganchu
Yanjun Sun
Martin Stogniew
Joshua E Allen
Gary L Olson
Original Assignee
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoceutics Inc filed Critical Oncoceutics Inc
Application granted granted Critical
Publication of DK3250208T3 publication Critical patent/DK3250208T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
DK16744237.5T 2015-01-30 2016-01-29 7-benzyl-4-(4-(trifluormethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on og salte deraf samt anvendelse deraf i terapi DK3250208T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562109737P 2015-01-30 2015-01-30
US201562148844P 2015-04-17 2015-04-17
US201562233757P 2015-09-28 2015-09-28
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy

Publications (1)

Publication Number Publication Date
DK3250208T3 true DK3250208T3 (da) 2021-01-04

Family

ID=56544438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16744237.5T DK3250208T3 (da) 2015-01-30 2016-01-29 7-benzyl-4-(4-(trifluormethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on og salte deraf samt anvendelse deraf i terapi

Country Status (26)

Country Link
US (5) US9845324B2 (da)
EP (2) EP3805222A3 (da)
JP (1) JP6802172B2 (da)
KR (2) KR102618971B1 (da)
CN (2) CN113149985A (da)
AU (4) AU2016211243B2 (da)
BR (1) BR112017016487B1 (da)
CA (3) CA3209515A1 (da)
CY (1) CY1123616T1 (da)
DK (1) DK3250208T3 (da)
EA (1) EA037552B1 (da)
ES (1) ES2839401T3 (da)
HR (1) HRP20201949T1 (da)
HU (1) HUE052821T2 (da)
IL (5) IL295286B2 (da)
LT (1) LT3250208T (da)
MA (2) MA55402A (da)
MD (1) MD3250208T2 (da)
MX (3) MX2017009841A (da)
NZ (2) NZ772369A (da)
PL (1) PL3250208T3 (da)
PT (1) PT3250208T (da)
RS (1) RS61243B1 (da)
SG (2) SG11201706062TA (da)
SI (1) SI3250208T1 (da)
WO (1) WO2016123571A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201706062TA (en) 2015-01-30 2017-08-30 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
KR20180125460A (ko) * 2016-01-29 2018-11-23 온코슈틱스 인코포레이티드 이미프리돈에 의한 g 단백질-커플링된 수용체 (gpcr) 조절
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
AU2017310526B2 (en) * 2016-08-12 2021-08-12 Edwin J. Iwanowicz Protein kinase regulators
US20200129596A1 (en) * 2017-03-13 2020-04-30 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT
WO2019197024A1 (en) * 2018-04-11 2019-10-17 Chemestmed Ltd. A method of modulating the rna methylation
JP7364664B2 (ja) 2019-03-26 2023-10-18 富士フイルム株式会社 Ｂ型肝炎ウイルスタンパク質の産生を阻害する医薬組成物、ｂ型肝炎を処置するための医薬組成物およびスクリーニング方法
WO2021154750A1 (en) * 2020-01-29 2021-08-05 Corcept Therapeutics Incorporated TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
AU2021321386A1 (en) * 2020-08-06 2023-04-06 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
EP4223876A1 (en) 2020-09-30 2023-08-09 FUJIFILM Corporation Double-stranded rna that inhibits production of hepatitis b virus protein, and pharmaceutical composition
CN113100233B (zh) * 2021-04-19 2022-02-08 中国农业科学院植物保护研究所 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7351729B2 (en) 2002-03-08 2008-04-01 Signal Pharmaceuticals, Llc JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070026402A1 (en) 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US20110287001A1 (en) 2008-09-22 2011-11-24 Tetralogic Pharmaceuticals Method of treatment
ES2668837T3 (es) 2008-12-11 2018-05-22 Abraxis Bioscience, Llc Terapia de combinación que incluye un taxano y un agente terapéutico adicional
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
EP2571877B1 (en) 2010-05-17 2018-08-15 Boehringer Ingelheim International GmbH 1h-imidazo[4,5-c]quinolines
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
WO2012138789A2 (en) * 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
PL2701708T3 (pl) 2011-04-29 2020-11-02 The Penn State Research Foundation Indukcja genu drobnocząsteczkowego trail przez komórki zdrowe i komórki nowotworowe jako terapia przeciwnowotworowa
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
AU2014244117B2 (en) * 2013-03-13 2018-12-20 Oncoceutics, Inc. Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
US9376437B2 (en) * 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
CN106163524B (zh) 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
CN106456643B (zh) * 2014-03-31 2020-04-17 斯克里普斯研究学院 用于trail诱导的药效团
KR20150114239A (ko) * 2014-04-01 2015-10-12 제일모직주식회사 내열성 및 착색성이 향상된 열가소성 수지 조성물
SG11201706062TA (en) 2015-01-30 2017-08-30 Oncoceutics Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用

Also Published As

Publication number Publication date
CN107427516B8 (zh) 2021-04-09
IL288525B (en) 2022-09-01
EA201791727A1 (ru) 2018-01-31
US10266533B2 (en) 2019-04-23
CN107427516B (zh) 2021-02-26
WO2016123571A1 (en) 2016-08-04
NZ733994A (en) 2024-04-26
EA037552B1 (ru) 2021-04-13
EP3250208A4 (en) 2018-10-03
CA2975476C (en) 2023-10-03
NZ772080A (en) 2024-07-05
US20170096431A1 (en) 2017-04-06
IL288525A (en) 2022-01-01
IL253689B (en) 2020-05-31
JP2021050209A (ja) 2021-04-01
AU2020286168B8 (en) 2022-09-22
IL253689A0 (en) 2017-09-28
KR102618971B1 (ko) 2023-12-27
US20240270746A1 (en) 2024-08-15
KR20170109583A (ko) 2017-09-29
JP6802172B2 (ja) 2020-12-16
EP3805222A3 (en) 2021-06-30
ES2839401T3 (es) 2021-07-05
IL295286B1 (en) 2024-06-01
US11976068B2 (en) 2024-05-07
AU2020286168A1 (en) 2021-01-07
US20190194201A1 (en) 2019-06-27
IL274135B (en) 2022-01-01
JP2018503663A (ja) 2018-02-08
US20220017519A1 (en) 2022-01-20
PL3250208T3 (pl) 2021-04-06
CN113149985A (zh) 2021-07-23
AU2024203421A1 (en) 2024-06-13
CA3209519A1 (en) 2016-08-04
AU2020286168B2 (en) 2022-06-09
BR112017016487B1 (pt) 2023-11-07
IL295286B2 (en) 2024-10-01
MX2021001096A (es) 2023-01-17
SI3250208T1 (sl) 2021-01-29
SG11201706062TA (en) 2017-08-30
CY1123616T1 (el) 2022-03-24
IL295286A (en) 2022-10-01
LT3250208T (lt) 2021-01-25
MA55402A (fr) 2022-02-02
EP3250208B1 (en) 2020-09-30
EP3805222A2 (en) 2021-04-14
CA3209515A1 (en) 2016-08-04
AU2016211243B2 (en) 2020-09-10
AU2016211243A1 (en) 2017-08-10
KR20240005186A (ko) 2024-01-11
MD3250208T2 (ro) 2021-02-28
IL274135A (en) 2020-06-30
PT3250208T (pt) 2021-01-06
IL312936A (en) 2024-07-01
EP3250208A1 (en) 2017-12-06
BR112017016487A2 (pt) 2018-04-10
HUE052821T2 (hu) 2021-05-28
CN107427516A (zh) 2017-12-01
MA41434A (fr) 2017-12-06
US20180072729A1 (en) 2018-03-15
MX2017009841A (es) 2018-02-09
MX2023000782A (es) 2023-02-14
RS61243B1 (sr) 2021-01-29
NZ772369A (en) 2024-07-05
AU2022228096A1 (en) 2022-09-29
CA2975476A1 (en) 2016-08-04
HRP20201949T1 (hr) 2021-01-22
US9845324B2 (en) 2017-12-19
MA41434B1 (fr) 2021-03-31
SG10201803508WA (en) 2018-05-30

Similar Documents

Publication Publication Date Title
DK3250208T3 (da) 7-benzyl-4-(4-(trifluormethyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-on og salte deraf samt anvendelse deraf i terapi
CY1124832T1 (el) 7-βενζυλο-4-(2-μεθυλοβενζυλο)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1 η)-ονη, τα αλατα της και οι μεθοδοι χρησης τους σε συνδυαστικη θεραπεια
RS65642B1 (sr) Supstituisani pirazolo(1,5-a)pirimidini i njihova upotreba u lečenju medicinskih poremećaja
DK3838274T3 (da) Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-derivat til brug til behandling af cns-lidelser
DK3345907T3 (da) Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
DK3313401T3 (da) Nanopartikler omfattende sirolimus og albumin til anvendelse i behandling af epithelioide celletumorer
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3212901T3 (da) Anvendelse af (2e)-1,1,1,4,5,5,5-heptafluor-4-(trifluormethyl)pent-2-en i effektcyklusser
EP2892085A3 (en) Slide battery and power tool for use with both slide and post batteries
IL245698A0 (en) Purines are converted in positions 2 and 6 and their use for the treatment of tumors
IL249228A0 (en) A pharmaceutical combination comprising a type iii receptor tyrosine kinase inhibitor and the histone-deacetylase-inhibiting fusion compound edo-s101 together with its use in cancer therapy
PL3481827T3 (pl) Pochodne imidazo[1,2-a]pirydyny, sposoby ich wytwarzania i ich zastosowanie
DK2406263T3 (da) Pyrazolo[1,5-a]-1,3,5-triazinderivater, deres fremstilling samt deres terapeutiske anvendelse
EP3344632A4 (en) Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
DK3292867T3 (da) Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
DK3172209T3 (da) Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
PL3271363T3 (pl) Atropoizomery halogenowych tetrafenylobakteriochloryn i chloryn oraz ich zastosowanie w terapii fotodynamicznej
DK3774795T3 (da) 4-(1h-imidazol-5-yl)-1h-pyrrolo[2,3-b]-pyridiner til anvendelse ved behandling af leukæmier, lymfomer og solide tumorer
EP3420695A4 (en) METHODS USED IN USER EQUIPMENTS AND ASSOCIATED UEs
PL3774141T3 (pl) Hydrauliczny uchwyt rozprężny i jego zastosowanie
EP3344625A4 (en) THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE
HK1225611A1 (zh) 用於預防或治療急性腎損傷的{4-[5-(3-氯-苯氧基)-噁唑並[5，4-d]嘧啶-2-基]-2，6-二甲基-苯氧基}-乙酸
PL3781554T3 (pl) Pochodne 2,6-diamino-3,4-dihydropirymidyn-4-onu i ich zastosowanie w terapii
PT3484892T (pt) Derivados de 1,2,4-triazolo-[3,4-b]-1,3,4-tiadiazole
DK3456720T3 (da) Hidtil ukendt krystallinsk saltform af 2,2-dimethyl-6-((4-((3,4,5-trimethoxyphenyl)amino)-1,3,5-triazin-2-yl)amino)-2h-pyrido[3,2-b][1,4]oxazin-3(4h)-on til medicinsk anvendelse